Document is current
Any future updates will be listed below
-
Authors
Funasako, Moritoshi https://orcid.org/0000-0002-1620-3924
Petrů, Jan
Hála, Pavel
Janotka, Marek
Škoda, Jan
Chovanec, Milan
Šedivá, Lucie
Reddy, Vivek Y.
Neužil, Petr
- License Information
-
More Information
Article History
Received: 14 December 2022
Accepted: 30 January 2023
First Online: 20 February 2023
Declarations
:
: This project was supported by scientific grant of Ministry of Health, Czech Republic - MHCZ-DRO (NNH, 00023884) IG220501. PN and VR have received speaking/honoraria from, and are consultants to CardioFocus. VR has disclosures with various cardiovascular companies unrelated to the current study. Consultant: Abbott, AtiAN, Biosense-Webster, BioTel Heart, Biotronik, Cardionomic, CoreMap, EBR, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences; Consultant, Equity: Ablacon, Acutus Medical, Affera, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics, EpiEP, Eximo, Farapulse-Boston Scientific, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, and Valcare; Equity: Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. All other authors have no disclosures to report.
